In contrast, diabetes trials with the sodium–glucose cotransporter 2 (SGLT-2) inhibitors empagliflozin and canagliflozin have demonstrated heart-failure risk reduction [32–34], whereas diabetes treatment with GLP-1 receptor agonists seem to have a neutral effect on the risk of heart failure [35–37]. This evidence concerns the gene SLC5A2 and diabetes mellitus.